Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immunogenicity of a third dose viral-vectored COVID-19 vaccine after receiving two-dose inactivated vaccines in healthy adults
Authors
Keywords
COVID-19, Inactivated vaccine, Virus vector, Immunogenicity, Booster dose
Journal
VACCINE
Volume 40, Issue 3, Pages 524-530
Publisher
Elsevier BV
Online
2021-12-03
DOI
10.1016/j.vaccine.2021.11.083
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sex differences in immune responses
- (2021) Takehiro Takahashi et al. SCIENCE
- Heterologous prime-boost: Breaking the protective immune response bottleneck of COVID-19 vaccine candidates
- (2021) Qian He et al. Emerging Microbes & Infections
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- (2021) Shabir A. Madhi et al. NEW ENGLAND JOURNAL OF MEDICINE
- COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials
- (2021) Zhi-Peng Yan et al. Pharmaceuticals
- Reactogenicity and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 in the UK: a substudy of two randomised controlled trials (COV001 and COV002)
- (2021) Amy Flaxman et al. LANCET
- Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- (2021) Joana Barros-Martins et al. NATURE MEDICINE
- Randomized Trial of a Third Dose of mRNA-1273 Vaccine in Transplant Recipients
- (2021) Victoria G. Hall et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of an Inactivated SARS-CoV-2 Vaccine
- (2021) Annelies Wilder-Smith et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines
- (2021) Mark G. Thompson et al. NEW ENGLAND JOURNAL OF MEDICINE
- Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study
- (2021) Sara Y Tartof et al. LANCET
- Role of IgM and IgA Antibodies in the Neutralization of SARS-CoV-2
- (2020) Jéromine Klingler et al. JOURNAL OF INFECTIOUS DISEASES
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- (2020) Merryn Voysey et al. LANCET
- Enhanced SARS-CoV-2 neutralization by dimeric IgA
- (2020) Zijun Wang et al. Science Translational Medicine
- IgA dominates the early neutralizing antibody response to SARS-CoV-2
- (2020) Delphine Sterlin et al. Science Translational Medicine
- Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18–59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
- (2020) Yanjun Zhang et al. LANCET INFECTIOUS DISEASES
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started